News for ADMA Biologics, Inc. (ADMA)

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

We recently published a list of 10 Firms End Stronger on Tuesday. In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against other firms that end stronger on Tuesday. A muted trading persisted on the stock market on Tuesday, with major indices ending in the red, recording minimal […]

We recently published a list of 10 Firms End Stronger on Tuesday.

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where ADMA Biologics Inc.

A bear market takes hold as Trump tariffs hammer stocks. IBD Leaderboard is trimmed to just seven names; safety and preparation are in focus.

Axogen and ADMA Biologics foresee minimal impact from President Trump's tariffs, highlighting strong domestic operations and resilient supply chains. Read more here.

The mean of analysts' price targets for Adma Biologics (ADMA) points to a 51.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Summary On April 7, 2025, ADMA Biologics Inc (ADMA), a commercial biopharmaceutical company, issued a press release emphasizing its strategic advantage due to i

Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based

**media[587683]**

Dow Jones futures: The stock market was mixed but generally higher ahead of big Trump tariff announcements. Tesla deliveries are on tap.

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

The latest trading day saw Adma Biologics (ADMA) settling at $20.25, representing a -0.15% change from its previous close.

Is it a good or bad thing when a stock experiences a golden cross technical event?

Adma Biologics (ADMA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The mean of analysts' price targets for Adma Biologics (ADMA) points to a 39.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Adma Biologics (ADMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

ADMA Biologics Inc (ADMA) showcases robust revenue projections with potential to exceed $490 million in 2025.Strategic FDA submissions and innovative productio

We recently published a list of Pulse of the Market: Wednesday’s 10 Top Performers. In this article, we are going to take a look at where ADMA Biologics Inc.